X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs DIVIS LABORATORIES - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD DIVIS LABORATORIES ORCHID PHARMA LTD/
DIVIS LABORATORIES
 
P/E (TTM) x -0.6 31.5 - View Chart
P/BV x 0.4 5.5 8.0% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ORCHID PHARMA LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
DIVIS LABORATORIES
Mar-17
ORCHID PHARMA LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1941,222 15.9%   
Low Rs35784 4.5%   
Sales per share (Unadj.) Rs276.5153.1 180.6%  
Earnings per share (Unadj.) Rs-79.239.9 -198.3%  
Cash flow per share (Unadj.) Rs-43.544.6 -97.4%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs53.9201.8 26.7%  
Shares outstanding (eoy) m70.45265.47 26.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.46.6 6.3%   
Avg P/E ratio x-1.425.1 -5.8%  
P/CF ratio (eoy) x-2.622.5 -11.7%  
Price / Book Value ratio x2.15.0 42.7%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m8,067266,266 3.0%   
No. of employees `0002.89.7 28.8%   
Total wages/salary Rs m2,5274,687 53.9%   
Avg. sales/employee Rs Th6,956.14,175.0 166.6%   
Avg. wages/employee Rs Th902.5481.5 187.4%   
Avg. net profit/employee Rs Th-1,993.01,089.3 -183.0%   
INCOME DATA
Net Sales Rs m19,47740,643 47.9%  
Other income Rs m407749 54.4%   
Total revenues Rs m19,88441,392 48.0%   
Gross profit Rs m1,10314,460 7.6%  
Depreciation Rs m2,5191,233 204.3%   
Interest Rs m5,22723 23,127.4%   
Profit before tax Rs m-6,23613,953 -44.7%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1253,349 -3.7%   
Profit after tax Rs m-5,58010,604 -52.6%  
Gross profit margin %5.735.6 15.9%  
Effective tax rate %2.024.0 8.4%   
Net profit margin %-28.726.1 -109.8%  
BALANCE SHEET DATA
Current assets Rs m11,01440,105 27.5%   
Current liabilities Rs m32,0606,595 486.2%   
Net working cap to sales %-108.182.5 -131.1%  
Current ratio x0.36.1 5.6%  
Inventory Days Days95119 80.0%  
Debtors Days Days3481 41.6%  
Net fixed assets Rs m29,44019,995 147.2%   
Share capital Rs m705531 132.7%   
"Free" reserves Rs m2,04353,043 3.9%   
Net worth Rs m3,80053,574 7.1%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51061,585 75.5%  
Interest coverage x-0.2618.4 -0.0%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.40.7 63.5%   
Return on assets %-0.817.3 -4.4%  
Return on equity %-146.919.8 -741.9%  
Return on capital %-3.726.1 -14.3%  
Exports to sales %37.90-   
Imports to sales %22.625.2 89.6%   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,40610,259 42.9%   
Fx inflow Rs m7,51335,384 21.2%   
Fx outflow Rs m5,64910,399 54.3%   
Net fx Rs m1,86524,985 7.5%   
CASH FLOW
From Operations Rs m1,68211,493 14.6%  
From Investments Rs m-9,860-11,372 86.7%  
From Financial Activity Rs m6,644-93 -7,136.2%  
Net Cashflow Rs m-1,53528 -5,404.9%  

Share Holding

Indian Promoters % 32.3 52.0 62.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 11.8 39.0%  
FIIs % 3.3 19.0 17.4%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.2 321.5%  
Shareholders   84,811 31,796 266.7%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jan 23, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - FRESENIUS KABI ONCO. COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS